Medical Device | June 05, 2026
Omnix Medical advances first-in-class antimicrobial OMN6 into Phase II trials
Targeting deadly drug-resistant acinetobacter infections
Targeting deadly drug-resistant acinetobacter infections
Anbalagan has led end-to-end product development programs from concept to commercialization, with a strong focus on regulatory compliance, process scalability, and manufacturing readiness
Dr. Lall brings extensive experience in healthcare operations, business strategy, and hospital management
DST-backed researchers from Pune demonstrate targeted gene-silencing approach that significantly inhibits tumor growth with minimal toxicity
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
Veteran pharmaceutical executive to relocate to Saudi Arabia and spearhead Cipla’s growth strategy across the Middle East region
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
